ORG-12962 is a pyridinylpiperazine drug developed by Organon, which acts as a potent and selective agonist for the 5-HT2 receptor family, with highest affinity at 5-HT2C and lowest at 5-HT2B subtypes. It was developed as a potential anti-anxiety drug, but was discontinued from human trials after tests in a public speaking challenge showed that its anti-anxiety effects were accompanied by side effects such as dizziness and a "spacey" feeling, which were attributed to poor selectivity in vivo over the hallucinogenic 5-HT2A receptor.

See also

  • 2C-B-PP
  • 2,3-Dichlorophenylpiperazine
  • 3-Chloro-4-fluorophenylpiperazine
  • CPD-1
  • ORG-37684
  • Quipazine

References



DIN EN 1296622005 DE Vertikale Verkehrszeichen

DIN EN 12952132003 DE Wasserrohrkessel und Anlagenkomponenten

DIN EN 129662015 DE Vertikale Verkehrszeichen

DIN EN 1262922003 Machines for the manufacture of constructional

DIN EN 1292922005 Safety requirements for cableway installations